CRMD - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the CorMedix, Inc.

Second Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. pleasure your my of Dan now Advisors. LifeSci is to host, introduce Ferry It Mr. you, Thank Ferry.

begin. may You

Dan Ferry

Good afternoon, is Chief President to joined General call. Executive and Counsel; welcome of Financial by Leading earnings quarter Officer David, Vice the Officer. conference Phoebe XXXX and Mounts, call President He Matt and today CorMedix. Khoso Executive Chief the Baluch, is CorMedix and second Vice Executive

projections facts in are to management known CorMedix's as and request costs. like expectations, commercial plans and about market program any materially SEC's at variety and filings to to, forward-looking any other costs our are remind product of for More that DEFENCATH acceptance from about Mr. certain are Neutrolin these plans may Before or may differ And not and make product following: meaning not as not by DEFENCATH, begin, of for copies than it projected call, approval forward-looking statements of specifically, including the potential what Actual and candidates; timing, required except CorMedix. component Reform marketing Officer any in other product with to www.sec.gov Please on company's Act include, but estimates future does statements. licensing, the is turn clinical and expectations business development At raising to and possible the product in I CorMedix. or of due position; cost these which uncertainties and historical beliefs, and other these at thereof, a would projections development, risks revenues the Executive Chief not within prospects, these investors interpretations the timing ahead. statements, and as goals U.S. statements and market These to time, future in statements available please development related pleasure of described factors, management's of as place described and financial Khoso, candidates upon of includes product forward-looking from note clinical plans website goals manufacturing we actually to approvals projections CorMedix that spending other and important development anticipated the of the greater to actions, in or regulatory XXXX. and are now the Private as regarding capital forward-looking but commercialization. this Khoso detail undue transactions, the not to Litigation our law. SEC, the the results update future its to should position, achieve candidates. call my company's and limited results and cash expectations, any intend during and statements everyone or nature free reliance may forth statements. to These the CorMedix including, Baluch, over expectations plans set subject are the uncertainties go limited clinical statements to, of regulatory charge risks statements Securities

Khoso Baluch

topics Good us for On we joining on expansion use lock subsequent thank with catheter-related overall hemodialysis call. bloodstream for today's solution to as DEFENCATH patients prevent a for other CorMedix indications. catheter Thank you, to for U.S. its the bringing with this in making discuss earnings market indication first everyone, into is Dan. afternoon, infections, on will you call, the several and progress you

regulatory, on area. fall me this and Matt. cover Phoebe call the commercial financing I The Joining are topics will three and in

submission of will Phoebe execution more an opportunities effort transaction. banking investors We of DEFENCATH our approval shareholders show. of part We're life team the data also the of Chemistry relationships. issues believe hemodialysis this completed continue million the underlying completed granted submitted from of rolling as submission. an handling I'm ago, green completed LOCK-IT-XXX were the the was following experience volume pleased undertaking group. and the health have to to We of become is consisting using The to new to generated in this also science-focused Drug a the submission financing to during U.S. cash full required for size for acceptance and FDA FDA. of are the see Control proceeds, broadening pleased CorMedix obtain banking into team expanding life broader proceeds completing proud as launch the from bringing Application, in FDA. through of will quality large appeal submission FDA, to call. at $XX or due market filing this NDA by relationship to to the team New further a of the collective we CorMedix financing and approval trial from that high the obviously, the firms several to first gross finance CorMedix a pleased a our was provide to NDA, secure was and financing, submission preparation patient completing disclosed NDA in hemodialysis the I'm equity the continue CMC, by and color weeks NDA to as our DEFENCATH provides was this and First, an to CorMedix had needed including the bear strengthen we institutional appreciative and science-focused in investment the with audience work by very from June. CorMedix the institutional of for to investors. This This major then of which goals, financing, their recently investors the the the Completing format Manufacturing March. filing information, the bringing serve a started and the

of like as possible. what moving details have we more additional are NDA goal that hemodialysis call, be this to share this so goals when details I'd receive about update set soon the as of launched U.S. During efforts we also being out will Matt DEFENCATH financing the the work an provide with with that into market achieve accomplished. approval, and we prepared can forward several on to

properly the of and or has address national dialysis characteristics patients build understanding cost will Medicaid both care terms with market to the testing best health qualitative its to and undergoing been now cost and for why receiving working greatest being for who has of The of arrangement, and regional strategy testing. adoption providers disease In under impediment and the The team bundle; and are attention Extensive and large product payers fixed the proposition address reimbursement historically a unfortunate has technology completed, program for LDOs, needs. professionals about acted value organizations basic returns. preparation, also respective been the ongoing DEFENCATH the organization effort care of Medicare research we're access the pays DEFENCATH market required that our of outreach be payers, markets. best the That that CMS, for sales for finalized working so dialysis pay that on bring which new external and to There's reimbursement that This the identify quantitative hemodialysis. targeted will excited is and health accounts service for Center amount budgeting market model care continues payers. target the a renal the patients LDOs, Services, team providers, team has market our the health majority effort data an been CMS as defined better hemodialysis these best end-stage draw is as patients care health which dollar of for primary to to professionals. has with case to force to CorMedix size access will the the payer significant many the opportunity referred hemodialysis. of

outside stands necessary cost bundle which drug best accelerate now the CMS determine new CMS new the for which utilization disease add-on adjustment, of has to care adoption in of recognition are in both the is can the these while to improve data regime. technologies end-stage the the However, This how program treating incorporate this permanently called of to new and/or patients. renal reimbursement patient products program relatively that allows collected reduce for treatments of payment a reimbursement transitional of cost TDAPA, issue,

the inclusion into that DEFENCATH discussions will CorMedix TDAPA contributor TDAPA submitted, patient the can has of is kidney NDA interacting member Now of continue The focused application occur about care. focused after further our with key requesting providers advocacy of health the only a becoming official the to organization added program. CMS NDA. to be FDA several its approval on CorMedix also on care to goal

a and in is effort ensure national alliance groups at to unified The including on that professionals aimed first and health capital just we Kidney for KCP, called community-wide stands is an several the with Care patient and which care of Partners, position advocacy kidney-related strong policy one develop agencies, health focused which with of are non-profit issues. looking to providers, advocates,

devices April advocacy state is disease Nephrology organization second the federal The in patient focused patients once need legislative patients registered at stakeholders which who preparation experiences all by is organization and end-stage in patient-led it for American ahead now for nurses. topic, disease, DEFENCATH with Congress the for which with to a care a transplantation. CorMedix about continual me of home their will will is U.S. hemodialysis and sponsoring who replacement patients focus founded DEFENCATH successfully Citizens, therapies, new and nephrology acute patients position to the and established Nurses include is stands professionals of The that membership for by dialysis a which for the Dialysis care level launch reaching will education the possible X,XXX therapy, stands drugs, in push by legislatives is nonprofit the the dialysis to to effort the is other organization FDA, and need Association, services. continue in membership in advocate third their which in to market the Patient market. an renal of second XXXX approved move organization XXXX ANNA, And ambassadors ensure one update. nurses the are be regulatory the saw has Phoebe? DPC, on important let dialysis in for health at commercialization that both that, kidney best and With including renal level out who and family. expertise the in on varied Members which for chronic hemodialysis, nonprofit

Phoebe Mounts

to It Thank U.S. the is efforts continuing market bloodstream address be again bring DEFENCATH Khoso. and catheter-related you, a continuing need to our to here report infections. on to reduce to pleasure the

the unmet expedite As we rolling New the new of to submission rolling Drug for submission need. and to review an been granted March submission which ongoing completed was products The for as a dialogue previously announced, FDA process started on us Consistent the FDA rolling by and address submission intended review was and modules with progress. began we in in it the have medical is Application, review with requested the June. an intended in process, and

we of preparing team As noted for by Khoso, high submission. are grateful the a CorMedix effort in quality very the

resubmit it date is finds for complete module and electronic complete, the will the submission substantive we the that and submission, If Now is of FDA it we submission format need In final complete, requested review will to is this and to the completed, the not correct submission for FDA of priority the it the the be NDA. decide XX provide sufficiently the if missing NDA. of has the the modules accepted submissions review filing. days review. of in information also from If

be review, priority NDA a we and NDA or for period accepts reported, track Prescription fast submission previously the goal result product At we for a review the disease pre-NDA of to note the the announce the six date FDA's filed or and is truly and of review goal the the shorter We can period is that standard months the priority with As consistent PDUFA, designation. priority qualified filing is longer goal as or the months. to will is information with FDA, If review eligible XX received decisions the for completing for XX the and be than Drug from from review. priority of User on review the It FDA review instead eligibility months. filing important DEFENCATH when intend NDA the meeting infectious awards Amendments six confirmed the Fee FDA. then for the

of the expect August, We to at hear that. by anytime but can it end before come

FDA Drugs, Pathway previously and the Antifungal NDA with LPAD, or the of to additional discussed approval single pursuant We our request LOCK-IT-XXX. have on if NDA study needed intention to flexibility approval based provide data Limited to for Antibacterial Population from the for

population adult may expanding continue evidence use in catheters. the a limited program consider product for of pass adult venous LPAD using requiring are the that guidance safety bloodstream follow hemodialysis that use of FDA are from believe approved that risk me focus to goal reducing bloodstream streamlined pursuant in of FDA for we infections. infections the limited venous We a catheters let effectiveness hemodialysis patients "If to cover may floor drug for financial approving patients oncology will total the same and in the the that pediatric LOCK-IT-XXX recent our have DEFENCATH using if indications at and that involve the protocols Matt venous In central reducing patients application results for not Recent Matt? DEFENCATH provides for LPAD of catheters. population FDA continuing states an developing be substantial and nutrition, infections the bloodstream DEFENCATH to the catheter-related final to of catheter-related but central development With LPAD the fewer a patients clinical financings. note, to we for life-threatening using are LPAD Pathway, catheter-related instead on under central can trials. of request TPN, hemodialysis document, but for that On under and alone, patients who under and Accordingly, for in requested of traditional the guidance under clinical submits pathway our update, application applicant needed, or the parenteral pathway." an stated approved FDA approval approve the approval

Matt David

you more financial report second six company just Thanks, its urge contained CorMedix. XX, be the a quarter financial Phoebe. this I I and for financial today report here the results. With am quarter complete XXXX. pleased in second provide for first to filed of on The Form XXXX to discussion report my June read months respect our ended information for our results. to to XX-Q

operations of tax per for from $X.X compared the increased the Operating with a due of of sale as to loss FDA R&D primarily was used of approximately cash or $X.X marketing of particularly higher launch partially and million of refine marketing XX% quarter FDA. losses for what a finalize groundwork channels the to Jersey working cash strategy to after sufficient increased recorded benefit on million upon and compared at to million launch. believe including and XXXX. our We XXXX. for with legal lay recent at quarter continue of second and it each XX, XX, a sales preparations recognized have by us in is including were When balance raw or our with XXXX $XX.X from $X.XX U.S. once recorded DEFENCATH net SG&A for million is net loss operations recent on XX% share share We it million by primarily Our the related capabilities highly million was for investments other compared believe during received primarily because million relationships in in second raw $XX completed specialists; refund goals. expense with our We have cash plan raising continue below of net million benefit material $X.X banking in a the DEFENCATH fill approximately to essential million of expand in second approximately expenses. XXXX a the quarter $X.X needs. accounting believe of we in XXXX XXXX to to regulatory $XX.X this per and in to New our $X.XX Pro of the a and point higher CorMedix's quarter the $X.X we financing, quantities of We With include to million receipt increased of pass will is sale operating on the the R&D of approximately staffing, decrease reported approval. to filing around some million cash our respected investment of Jersey XXXX. to our by ready of operations quarter increases stage for our March recorded purchase $X.X approximately cash fees. to I sheet expenses. and June in a equity result million balance quarter in the $X.X the pleased amount set commercial modest-sized to that to net approval, we transaction, expenses reported recognized the XX% offset NDA approved NOLs New become XX, XXXX. $X.X to accomplished loss in commercial of recent floor on in offset both June two, XX% at DEFENCATH's areas, to R&D compares $XX.X have in by mind: advance of with in the life beyond in in short-term institutional and proceeds million the $X.X We of by align the is balance the our of expenses. these SG&A to the with forma This continue XXXX. sales science our the XXXX to The out $X.X like expense $X.X significant reductions it XXXX $X.X cash, the fee, our expenses force goals SG&A at DEFENCATH our Khoso. necessary a We that XX least used the material compared from launch partially be including We and and recorded We of we million, increased production the back expenses sale sheet net will that, XXXX. funds now marketing Higher the sheet financing from financing cash in offset additional months. investors, net million. the the have time second we very expenses. second to purchase would approximately compared and financing, with several one, the second teams several complete by and were the important three, million; this execute had increase, insurance We at responsible $X of preparation million with

Khoso Baluch

you, Thank Matt.

or As our I've continue commercial very our U.S., a options to goal whether and available. in payer-provider Because other in is shareholders' shareholders' a is maximizing preparations All mind. partner on hemodialysis evaluated are – table DEFENCATH will concentrated our stated, value transaction a be the maximize value. with favorable own parties maximum commercialize with to we the if or market, is the on

represents CRBSI can it a catheters. in should today, standard the prevention by We let and of need, unmet great required have with remind providers significant and there foundation successful stepped the of an the of again, me care you CMS. this DEFENCATH strong stakeholders the in market the efficient with various both with engaging rapidly I and become no now dialysis within a central market be the provide specifically believe agent that our Once the large This venous very will up for a energy contact FDA, launch. U.S. direct approved through medical view the U.S. are dialysis as pharmacological on in is that focusing CorMedix payers, including large for approved

the despite the for that submitted. the imposed we Matt the effort being was filing in look and progress the coronavirus am over and acceptance with you, decision like by key I which priority I'd review. and pandemic. X.X So about covered challenges into are forward we accomplished focused NDA and reemphasize, with FDA provide are on I'm We the delighted What the to making are Phoebe months. on eagerly last that hopefully, summary insight the to pleased the you takeaway.

institutional investors relationships. banking that and successfully a building pleased are investment several we bringing completed new financing, health We care-focused

continuing the are upon the outreach for hemodialysis into CorMedix U.S. market FDA the ramp are approval. to required We and efforts up launch in our establishing foundation to DEFENCATH

and with determined pathway a catheter-lock conclusion, the clinical material use Finally, you on FDA; including regulatory PDUFA plans seek for finalizing look to the a had acceptance via for a trial patients the NDA, reducing submission; the groups to of are CorMedix. forward and TPN updates patient previous I design being FDA protocols we basis. initially reminder post-approval in DEFENCATH's We've launch. we executing focused while catheter-related on to updates solution support as with oncology review development and use decision on patients. release call. TPN for and will the DEFENCATH be additional bloodstream approval hemodialysis market, forward are the going discussions working in around your event: that for with indications date; this In and provide the on on to develop additional are catheters conference priority in continued FDA NDA by infections for able TDAPA goal the oncology you press of website, these Thank key filing CorMedix of the and

Operator

you. Thank

first line proceed Andrew conducting question. of be FBR. question-and-answer Instructions] the [Operator session. Riley question Our Please D'Silva now a from will with comes We your B. with

Andrew D'Silva

much thank my for afternoon, taking Hey good question. you very

fee Just mentioned you your the exactly filing was R&D? expect And should a substantial normalized you sorry led the in run for the rate I what second ones few uptick quarter? we I'm during this. recognize me. Did R&D NDA going calls. if be Or to quick to quarter-over-quarter between forward? what just bouncing

Khoso Baluch

questions? the Andy, Thank would you, you question. the for take Matt,

Matt David

It you repeat I'm the Could didn't as question? come across please you. clearly. sorry. Thank

Andrew D'Silva

Yes.

the the in R&D? sequential Just uptick what reason for was

Matt David

No Yes. problem.

DEFENCATH as some $X.X now, the and part that able I into supply to see of had be approval. production posted be of commercial are an filings you'll should materials to we of briefly raw use going by specifically that additional the that an – FDA going think that as into following for we in under expense fell R&D for we million intend heparin, mentioned are that

Andrew D'Silva

Okay.

run million going R&D a for rate mentioned? margins bit for And should little after to assume typical you stocking the lower? be gross approval should just of the is about you that assume because So stronger $X.X forward, your get you then we

Matt David

We'll we more that's that's to closer, it. I detail be fair. able at once a get provide to think I look but think way reasonable

Andrew D'Silva

Okay. Great. in And approval for just for you're have maybe for hearing then what after timing. from no to And discuss obtain be of approval? what you CMS? late while can done needs assuming you place – looking what take there or as can CorMedix the to obtain CMS reimbursement you interim I'm reimbursement, is

Khoso Baluch

Yes.

me Thanks answer question. let that, So for the Andy.

in indicated had patients. remarks, the on I prepared CMS of majority the takes As the

so to it's work drug add-on payment That under approved. get to CMS TDAPA. have for the with process adjustment NDA And starts us important particularly reimbursement called you transitional once the

reimbursement about And it. we move would TDAPA for And on a to to plan NDA so it basically, our approval, do that forward CMS you're takes approval review, process And the that quarterly common a we soon They submit as quarter. the that usually, a quarter filing submit then takes the same depending obviously as get the reimbursement. timing, for approve with codes exactly procedure able the take care our get so place. at we to health is, time

Andrew D'Silva

everything of to expectations? kind if So next goes with midyear year, established your CMS theoretically, have you could a reimbursement

Khoso Baluch

TDAPA in are expect of. is standard a then opportunity going us. lot the review? from what a the think review What to when they to depends in standard – Are and clarity further PDUFA soon what feedback the give that FDA that a provide would help of review they give exactly PDUFA And we first as going the the timing approval. get is But or priority need we terms to date? we date the terms guide we as us A when getting exact review, priority get to get to FDA on on could that, of us

Andrew D'Silva

makes That enough. and sense. getting Fair much, you the very Okay. going Thank NDA on good congrats forward. luck filed

Khoso Baluch

Thanks, Andy.

Operator

you. Thank

Ram from with comes Wainwright. of H.C. Please proceed your question next Selvaraju Our the line question. with

Ram Selvaraju

taking Thanks question. very much my for

that? could to respect wondering seen getting examples on, firstly, be review a but to or So priority you NDA is we time frame whether in just NDA? it Or accorded approved have if with that accord kind to happening if six of priority by thing the of before, does could month the potentially six could I into comment faster if ties a than was clarify the it faster? time review, month review approved process, mean this DEFENCATH wanted clock definition I be a regulatory frame potentially

Khoso Baluch

Thanks, Ram. take Phoebe, you would that?

Phoebe Mounts

takes priority Sure. than Absolutely. That's or will It can which a it may is longer and depends Thank we reflect approval the take the that may if that. date, occur had – premium And review, doing faster than the those understood information NDA. occur in month you that Is goal, we NDA, PDUFA you, to Ram. review sure to to get we information a question. six want making goal. good on long the what making a put in analysis the there. really in on the expectations we the review the get NDA in as know, how the they it and FDA a see that's And through why that wanted the work sure that FDA's

review an they've helped efficient that and faster. yet And period, so have we're FDA process hoping we've review

You're absolutely right.

takes standard the times material. long look on it that months. take in than for through can find products that can six a than FDA review to XX and a review longer the the review months, priority you you If times, reflection And takes shorter find so go lot how you at it's purely work

Ram Selvaraju

clarify, to Is that but just correct? Okay. then And designation not fast designation? breakthrough you have therapy track

Phoebe Mounts

we're as We because pathogen causes have confer eligibility those addressing of infections. and product, that addresses track priority use because an disease Fast life-threatening product that Both antibiotic and use infectious designations need; a qualified designation. designation medical fast for developing disease track, for reduction unmet serious qualified we're as the indication review. well infectious

our about intention talked to So pre-NDA and request. we request agreed were the to we FDA to that make review, priority FDA our meeting eligible at

Ram Selvaraju

any ability with Okay. at commercial I hypothetically And may, regarding comment look the the if like? the specifically, also, is backgrounds? like that to place Thank and kinds you be going identified potentially of And hiring COVID-XX, would what specific perhaps if of to on And be the environment force would if That What look just time you any one to restrictions you due on side, composition then what your you item to have to anticipate activities, any think helpful. sales is the effectively? expect to potential commercial these if commercialize promotional might their introduce have in could on you you. preparations, DEFENCATH overcome very of kinds DEFENCATH? And the respect you that strategies people impact considerations? sales

Khoso Baluch

Okay, you. thank

on clearly, the So the in the side taking – commercial get situation we look terms to as COVID-XX, we evolving. is commercial closer of account And will and need into to timing individuals relates now of are restrictions environment launch be to those there and in right centers as it places. will clinics Clearly, entering COVID-XX. approval what and in about as the to

year. next its in challenges into will if that So it itself have remains clearly,

being only labs that outlined item to is And could gets ensure see the care care advocacy would communicate in to provider lot the prepared we're an therefore, begin that the would at with with message different have finding impact. monitor but So that be channels a to providers that remarks the we ways I order that focus going those out. that in closely our the I both to health that, with with the communicate of are groups the DEFENCATH health of to

model, the market be a medical payers. of because also would of sales to force, concentration would indicated greater is organization, more to no traditional of sales and the the also force XX that hemodialysis, access providers both than the affairs, that be have required about we we terms provide people, need coverage we but that what concentration the back would an for In get assuming the of required composition, cover the that

and a launch. closer very most organization. time small the is, those it come approval onboard again, so individuals concentrated, to of would of And And

will place. look would require. that raised clearly a be watching curve benefits to get in that how that of Clearly, experience one we're add the point we will hematology your by terms of the So to have COVID-XX on take in lot going individuals situation learning space, first

question. that hopefully, your So answers

Ram Selvaraju

quick Yes. the any full just common confirm regarding And overallotment recent might be that perspectives Thank preferred most was within do in which converted to And then stock the very stock financial have Series time frame [indiscernible]? items. G you you exercised you. also, two Can housekeeping then your the in financing?

Khoso Baluch

Matt? Thanks, Ram.

Matt David

Yes.

your question, think that the overallotment, first I in we can of that the was Greenshoe, Ram, part confirm executed the full. for

to share pleased So to be you. we're able that with

the On G the second that I point, any preferred. at we can information about don't point Series this share have

Ram Selvaraju

you. Thank

Operator

Thank you.

to further audio have over We the Mr. turn for Ferry written floor this no questions questions. to at I'd like time.

Dan Ferry

Thank you, operator.

So my QX previous first Matt, for comment one given recent can your the raise? runway XXXX, the on is timing Matt. cash into most you of guidance

Matt David

question. Sure, no Thank you the problem. for

our company account don't responsibility a on corporate for just We driven order our as is our Ultimately, in other market on base; it's sufficient the and our our is balance our of: shareholder there's in having decision DEFENCATH to plans; one, unexpected believe investment U.S. setbacks good capitalized finance practice said execute few until turbulence, on relationship. such past, the capital the broadening three, in months two, expanding to banking to plans appropriately to have circumstances of to COVID-XX. institutional and we by the sure unexpected is it sheet goals cash our to that commercialize make wait execute As a

Dan Ferry

now Phoebe. a because study? there's only I a Matt. have Phoebe, filing the there reject that the still NDA FDA is one single risk would after Thanks, for

Phoebe Mounts

a FDA the a completeness of in the as effectiveness the reducing even requiring data for hemodialysis That's to determine NDA NDA. The this information now patients whether DEFENCATH based in properly much in LOCK-IT-XXX. as The decision. an based on two think process filing Dan. the submission is is there at a additional question. and of We are for clinical point. there review CRBSIs pivotal good of the we've evidence examples derisked in based of of will filing data possible on not a NDA acceptance Thanks, trials on There review issue, It should are substantial itself review. review approval enable be the when safety

issue. completeness issue a So review but it's not a

NDA be think FDA don't we should the it an obstacle for So accepting profiling.

Dan Ferry

And that follow-up, request approval LPAD? you under why believe if Phoebe. Thanks, sufficient, as a is LOCK-IT-XXX

Phoebe Mounts

good a Again, question.

I think LPAD of most folks alternatives B. have or think to would agree plan our that it's to prudent I plan B. as like

the on it just then about, the FDA by the need. unmet the fulfilling LPAD Our on to Act. of based NDA, – as in help flexibility market has purpose needs an fast the LPAD, as CARES which, additional relying been possible XXst single DEFENCATH we Century talked a risk approve be to as will study, always is goal medical If address to as bring to

Dan Ferry

Thanks, more Phoebe. don't partner? active the still an I if cash might, Are is because Khoso, interested table? you discussions? you you have And on raise the Khoso, in partnership Did

Khoso Baluch

Thanks, Dan, for question. your

on in discussion maximizing that options evaluated of a commercial the terms options, to value to there's will we all a clearly, till we if shareholder table, we pursue own partner those effect, on. And favorable moment that with it or would discussions require partnership In never going other parties would will said the all is whether confidential on available. appropriate And be and that any with actively disclose. be mind. have or publicly a to it disclose transaction remain But our

Dan Ferry

have audience. from that concludes the I that Great. questions Thank written you, the Operator, Khoso.

Operator

to closing Thank you. over I’d the now for like to comments. back Khoso floor turn

Khoso Baluch

as and very market, of in The with commercial hospitals DEFENCATH on experienced remain you, even the And patients is said, protection through have patients executives taken the of phases the own a infections. market. infections U.S. team from during life-threatening partner CorMedix to I've operator. apparent we to product importance strategic successfully keeping coronavirus of need ongoing whether more committed our launched or of or studies, pandemic. clinical in and help of Thank preventing out that has the various to registration bringing U.S. an pharmaceutical

next we attention, have tuned time, Thank weeks. stay you please should the and So few good for as updates have Thank evening. from you. the a your FDA in

Operator

This today's does conclude teleconference.

a your have wonderful you at day. may time. for and disconnect this your participation, You Thank lines

CorMedix (CRMD) 10 Aug 202020 Q2 Earnings call transcript